RASSF1A和TIP30在大肠癌中的表达及临床意义

RASSF1A and TIP30 Expression in Colorectal Cancer and Its Clinical Significance

目的探讨RASSF1A和TIP30在大肠癌的发生、恶性转化、侵袭和转移的作用和临床意义.方法应用免疫组织化学法检测大肠正常组织、大肠癌组织和大肠癌旁组织中RASSF1A和TIP30蛋白表达.综合分析它们与患者的年龄、性别、分化程度、淋巴结转移等临床病理因素相关性.采用Spearman等级相关分析RASSF1A和TIP30的相关性.结果在大肠正常组织、癌旁组织和癌组织中RASSF1A阳性率分别为90%、72%、16%,TIP30阳性率分别是95%、70%、13%,在大肠癌中RASSF1A和TIP30的表达与淋巴结转移、浸润深度、分化程度有关(P<0.05).Spearman等级相关分析RASSF1A和TIP30的表达呈正相关(rs=0.292,P<0.05).结论 RASSF1A和TIP30与大肠癌的发生、恶性转化、侵袭和转移的作用有关,可能作为大肠癌的早期诊断和预后判断的一种新的潜在的分子标志物,对大肠癌患者早期诊断,评价恶性程度,指导临床治疗,判断预后具有一定临床意义.

Objective To investigate the expression of RASSF1A and TIP30 in colorectal cancer and evaluate the clinical significance in tumorigenesis, malignant transformation, invasion and metastasis. Methods The expression of RASSF1A and TIP30 was detected by immunohistochemistry method in normal colorectal tissues, colorectal carcinoma and adjacent tissues of colorectal carcinoma. The correlation between their expression and the clinicopathological data of patients, including age, gender, the degree of differentiation, lymph node metastasis, was comprehensively analyzed. The correlation between RASSF1A and TIP30 was analyzed by spearman＇s rank correlation. Results The positive rates of RASSF1A in normal colorectal tissues, adjacent tissues of colorectal carcinoma, colorectal carcinoma were 90%, 72% and 16%, respectively, and TIP30 were 95%, 70% and 13%, respectively. The expression of RASSF1A and TIP30 were related to lymph node metastasis, depth of invasion and degree of tumor differentiation （P 〈 0.05）. Spearman rank correlation analysis showed that positive correlation was showed between RASSF1A and TIP30 （rs = 0.292, P 〈 0.05）. Conclusions The expression of RASSF1A and TIP30 are ralated to colorectal tumorigenesis, malignant transformation, invasion and metastasis, and may be as new potential molecular markers for early colorectal tumorigenesis diagnosis and prognosis, and have a certain clinical significance for early diagnosis, evaluation of the degree of malignancy, clinical treatment and prognosis of patients with colorectal tumorigenesis.